To include your compound in the COVID-19 Resource Center, submit it here.

Keep It Simple

Clinical Data depression drug approved on new dosing regimen, not biomarkers

Genaissance Pharmaceuticals Inc. thought it would leverage its pharmacogenomics expertise in 2004 when it acquired Viibryd vilazodone, a compound that had failed five Phase II trials for depression. But the problem with Viibryd turned out to be a lot simpler. Clinical Data Inc., which acquired Genaissance in 2005, conducted a pair of successful Phase III trials using an optimized dose and titration schedule, and FDA approved the drug last month for major depressive disorder.

Genaissance was founded in 1997 as a pharmacogenomics service provider, based in part on technology that came out of another company founded in 1992, Bios Laboratories Inc.

After 12 years and $172 million in fundraising, Genaissance found itself with the

Read the full 1126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers